Pique Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Pique Therapeutics, Inc.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group: A New Perspective on Cancer Immunotherapy, features profiles of Apthera, Juvaris BioTherapeutics, Pique Therapeutics and Vaxon. Plus these Start-Ups Across Health Care: Acceleron Pharma, CTG Pharma, ImVisioN, and Innovent Medical.
Many attempts to develop therapeutic cancer vaccines have focused on boosting immune system response to vanquish naturally immunogenic tumors. Pique Therapeutics is instead creating vaccines against non-immunogenic tumors, which since they don't stimulate the immune system, have never developed a way to evade it. Pique reasons that if those tumors can be made visible to the immune system, they will prove more susceptible to being overcome than tumors that are accustomed to fighting.
In Vivo briefly summarizes the technologies of these recently founded companies: Cellca, InVivo Therapeutics, Kenta Biotech, Parsortix, Pique Therapeutics and Proprius Pharmaceuticals.